- Previous Close
6.54 - Open
6.54 - Bid 6.62 x 200
- Ask 6.51 x 200
- Day's Range
6.51 - 6.74 - 52 Week Range
2.31 - 9.18 - Volume
116,704 - Avg. Volume
877,383 - Market Cap (intraday)
511.209M - Beta (5Y Monthly) 2.18
- PE Ratio (TTM)
59.77 - EPS (TTM)
0.11 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.82
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
www.niagenbioscience.comRecent News: NAGE
View MorePerformance Overview: NAGE
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NAGE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NAGE
View MoreValuation Measures
Market Cap
508.49M
Enterprise Value
466.63M
Trailing P/E
59.45
Forward P/E
54.64
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.13
Price/Book (mrq)
11.03
Enterprise Value/Revenue
4.69
Enterprise Value/EBITDA
50.67
Financial Highlights
Profitability and Income Statement
Profit Margin
8.59%
Return on Assets (ttm)
7.84%
Return on Equity (ttm)
22.94%
Revenue (ttm)
99.6M
Net Income Avi to Common (ttm)
8.55M
Diluted EPS (ttm)
0.11
Balance Sheet and Cash Flow
Total Cash (mrq)
44.51M
Total Debt/Equity (mrq)
5.75%
Levered Free Cash Flow (ttm)
9.61M